KALV vs XOMA vs PRAX vs HALO vs RARE

For growth investors, XOMA Royalty Corp.

(XOMA) is the stronger pick with 83. 1% revenue growth year-over-year, versus -100. 0% for Praxis Precision Medicines, Inc. (PRAX). Halozyme Therapeutics, Inc. (HALO) offers the better valuation at 25. 5x trailing P/E (8. 1x forward), making it the more compelling value choice. Analysts rate KalVista Pharmaceuticals, Inc. (KALV) a "Buy" — based on 13 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Halozyme Therapeutics, Inc.

(HALO) is the cheapest at 25. 5x versus XOMA Royalty Corp. at 28. 3x. On forward P/E, Halozyme Therapeutics, Inc. is actually cheaper at 8. 1x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Halozyme Therapeutics, Inc. wins at 0. 35x versus XOMA Royalty Corp. 's 2. 75x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Halozyme Therapeutics, Inc.

(HALO) delivered a total return of +37. 0%, compared to -77. 2% for Ultragenyx Pharmaceutical Inc. (RARE). Over 10 years, the gap is even starker: HALO returned +570. 7% versus RARE's -59. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Halozyme Therapeutics, Inc.

(HALO) is the lower-risk stock at 0. 56β versus Praxis Precision Medicines, Inc. 's 1. 55β — meaning PRAX is approximately 177% more volatile than HALO relative to the S&P 500. On balance sheet safety, Praxis Precision Medicines, Inc. (PRAX) carries a lower debt/equity ratio of 0% versus 157% for XOMA Royalty Corp. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), XOMA Royalty Corp.

(XOMA) is pulling ahead at 83. 1% versus -100. 0% for Praxis Precision Medicines, Inc. (PRAX). On earnings-per-share growth, the picture is similar: XOMA Royalty Corp. grew EPS 188. 5% year-over-year, compared to -32. 0% for Praxis Precision Medicines, Inc.. Over a 3-year CAGR, XOMA leads at 105. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

XOMA Royalty Corp.

(XOMA) is the more profitable company, earning 60. 8% net margin versus -1391. 1% for KalVista Pharmaceuticals, Inc. — meaning it keeps 60. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HALO leads at 58. 4% versus -1343. 0% for KALV. At the gross margin level — before operating expenses — XOMA leads at 94. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Halozyme Therapeutics, Inc. (HALO) is the more undervalued stock at a PEG of 0. 35x versus XOMA Royalty Corp. 's 2. 75x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Halozyme Therapeutics, Inc. (HALO) trades at 8. 1x forward P/E versus 36. 7x for XOMA Royalty Corp. — 28. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for RARE: 97. 1% to $51. 50.

In this comparison, XOMA (0.

7% yield) pays a dividend. KALV, PRAX, HALO, RARE do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Halozyme Therapeutics, Inc.

(HALO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 56), +570. 7% 10Y return). Praxis Precision Medicines, Inc. (PRAX) carries a higher beta of 1. 55 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (HALO: +570. 7%, PRAX: -20. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: KALV is a small-cap quality compounder stock; XOMA is a small-cap high-growth stock; PRAX is a small-cap quality compounder stock; HALO is a small-cap high-growth stock; RARE is a small-cap high-growth stock. XOMA pays a dividend while KALV, PRAX, HALO, RARE do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.